Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia
CAMBRIDGE, Mass. and SHANGHAI, China, May 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has entered into a License Agreement with
View HTML
Toggle Summary Vericel Reports First-Quarter 2017 Financial Results
Conference Call Today at 8:00am Eastern Time
View HTML
Toggle Summary Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
Ixmyelocel-T is the First Therapy to Receive the RMAT Designation for the Treatment of a Serious Cardiovascular Disease
View HTML
Toggle Summary Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:         Vericel
View HTML
Toggle Summary Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 5th
View HTML
Toggle Summary Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
Accomplished Industry Veteran Brings Extensive Quality and Regulatory Affairs Experience in Cell and Gene Therapies and Medical Devices
View HTML
Toggle Summary Vericel to Present at the 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 16 th
View HTML
Toggle Summary Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
CAMBRIDGE, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the presentation of Epicel ® (cultured epidermal autografts [CEA])
View HTML
Toggle Summary Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results
Record Revenues of $16.5 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious
View HTML
Toggle Summary Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:  Vericel Corporation
View HTML